If you are new to POH or just want a quick summary, have a look:
Proven platform delivery technology "TPM" applicable to multiple industries and thousands of products (currently Drugs, Supplements and Food for animals and humans, Personal Care)
Company Fully Funded for current programs
Approx $30 mill in cash
Cash burn close to zero
Revenue streams increasing rapidly with personal care sales approx. $1 mill a month current. Likely $20 mill+ total by end of fin year.
Approx 1 billion shares on issue.
New deal added today for India - Diclofenac Gel
1yr approx until the world first Oxycodone patch phase 3 is completed. Likely to take $1 billion plus market share from Oxycodone tablets in US alone. Can also replace $1.2 billion market for the dangerous fentanyl patches. This patch will reduce oxycodone abuse, tolerance and remove breakthrough pain.
3M, Novartis, CSL are some of the Phosphagenics partners.
26 known projects
12 funded fully by partners
Trials are testing TPM delivered, already FDA approved, drugs and are therefore much simpler, faster, cheaper and at the lowest risk.
1 x phase 3
3 x phase 2
4 x phase 1
TPM enables safe non irritation delivery of compounds through the skin.
TPM is a technology based on Vitamin E and has inherent powerful anti inflammatory properties.
TPM enables compounds much larger than previously possible to go through the skin without injection or with damaging skin disruption.
TPM also increases the effectiveness of these compounds by 400-1000% enabling less active to be used.
TPM can be used orally, as a cream, spray, foam, gel, or patch.
POH Deals fully funded by partners:
1) Insulin Animal Novartis Animal Health Deal March 2010 Ongoing Initial payment, milestone, royalties if products utilised
2) Vaccines(Large Proteins) CSL Deal June 2009 Ongoing Option, milestone, royalties - if products produced
3) Dermatitis/Psoriasis Topical Steroid US Dermatology Company(undisclosed) Deal Q1 2010 Phase 1 started Q2 2011 If option to license is taken will fully fund to registration as topical drug. Milestone and royalty payments.
4) Acne Major Global Dermatology Company(undisclosed) (Bayer, Galderma, GSK, Novartis, Merck, Sanofi-Aventis, J&J) Started April 2010 Clinical trial starting Q4 2011
5) Mastitis Mastitis Management Australia Deal Feb 2011 License Aust/New Zealand Available Q4 2011
6) Cosmetics Le Metier Deal July 2009 50/50 profit share 2 products released early 2010 10 products available Q3 onwards
7) Shampoo(delivery of actives into scalp) Rodney Cutler Deal April 2011 Product release Q1 2012 US, UK, Australia Royalties
8) Cosmetics- Global Cosmetics Company(undisclosed) Deal Q1 2010 ?????
9) Over the Counter Phusion Labortories Deal March 2010 50/50 Joint venture with ProPhase(formerly Quigley) 10% ownership of Prophase $1 million upfront Launch 2012
10) Cosmetics- Global Cosmetics and Dermatology Company(undisclosed) Deal September 2011 Human study of new cosmetic product
11) Personal Care – Mass market licence and partnership under negotiation October 2011 – investor presentation
12) Pain – Diclofenac(anti inflammatory) topical gel(best known as Voltaren) Themis Medicare Pvt Ltd Mumbai India Nov 2011 – product must be on shelves within 12 months Upfront payment Double digit royalties Exclusive deal for India 2000 oulets throughout India
POH self-funded commercial projects:
1) Cosmetics Elixia ranges (14 products) Asia(Watsons 9000 outlets), US, Australia Includes proven fat burning cellulite cream peptide AOD9604 exclusively
2) Supplements International Specialty Products (ISP) Vital ET
3) Pain - Oxycodone(opioid) Oxycodone twice weekly Patch 3M doing commercial production First and only oxycodone patch Major anti abuse properties(abuse is a massive problem) Phase 3 trials Q4 FDA approval 2012
POH projects being shopped around:
Licensing to be sought for other products – investor presentation Sept 2011
1) Insulin Human - Basal Insulin First and only to get insulin through the skin and by patch. Phase 2 trial successful - Jan 2009
2) Pain/anaesthetic Lidocaine Topical Lidocaine 5 times more effective than non TPM lidocaine Phase 1 successfully completed Dec 2008
3) Pain - Diclofenac(anti inflammatory) Diclofenac(Voltaren) Phase 1 trial successfully completed Feb 2009 4 times more effective than non TPM Voltaren treatment for Actinic Keratosis proof of concept Q3 2011 Licensing to be sought – investor presentation Sept 2011
4) Supplements Animal Feed Increases the benefits of vitamins and trace elements for animal health
5) Mastitis Global Improves the cows natural resistance to mastitis Enables cows to be brought back into milk production and health 15% of all cows worldwide at any time suffer mastitis
6) Supplements Vitamin D Deficiency of Vitamin D cause many health issues People in temperate climates have deficiency due to lack of sun exposure
7) Supplements Dietary supplements Significantly improved oral bioavailability, absorption and efficiency of vitamins/nutrients
8) Supplements Functional foods Significantly improved oral bioavailability, absorption and efficiency of vitamins/nutrients in foods
(20min delay)